|
|||
|
2017, Cilt 47, Sayı 1, Sayfa(lar) 011-020 |
[ Türkçe Özet ] [ PDF ] [ Benzer Makaleler ] |
Relationship Between Pegylated Interferon-Ribavirin Treatment Response and Chemokine Ligand and Receptor Levels in Hepatitis C Virus Infected Patients |
Orçun ZORBOZAN1, İlknur KALELİ1, Hüseyin TURGUT2 |
1Pamukkale Üniversitesi Tıp Fakültesi, Tıbbi Mikrobiyoloji Anabilim Dalı, Denizli 2Pamukkale Üniversitesi Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Denizli |
Keywords: Delta 32, chemokines, host-virus interactions |
Objective: Antiviral agents used in chronic HCV infection
treatment have serious side effects. HCV-RNA is used to
evaluate treatment response. HCV genotype is used for
determining duration and dose of treatment but there is no
definite predictor of treatment response yet. This study is
designed to investigate the relationship between chemokines,
chemokine receptors, delta-32 deletion and HCV infection
treatment response.
Material and Methods: Fifty chronic HCV-infected patients and 28 healthy controls were included in the study . Serum CCL3, CCL4, CCL5, CXCL9 and CXCL10 levels were measured by commercial ELISA kits. CCR5 and CXCR3 surface expressions of peripheral blood CD8+ cells were evaluated by flow-cytometry. Delta-32 deletions were evaluated by real-time PCR. Results: Patients were divided into two groups according to their treatment responses. In both of the patient groups, percentages of CCR5+-CD8+ lymphocytes and CXCR3+- CD8+ lymphocytes were higher than those of the control (p=0.001, p=0.021, respectively); but there was no significant difference between patient groups (p=0.872). CCL3, CXCL9 and CXCL10 levels were significantly higher in patient groups than those of the control. CCL4 and CCL5 levels were not significantly different among responders, non-responders and contro subjectsl. CCL3, CCL4, CCL5 and CXCL9 levels were not significantly different between responder and nonresponder patients, while CXCL10 levels in non-responders were higher than those of responders (p=0.001). Conclusion: According to the findings of this study, CCR5 and CXCR3 surface expressions of CD8+ cells in the peripheral blood increased in chronic hepatitis C but there was no difference between responder and non-responder patient groups; CCL3, CXCL9 and CXCL10 levels increased in HCV infection, however, only CXCL10 predicted the treatment response. |
[ Türkçe Özet ] [ PDF ] [ Benzer Makaleler ] |
|